Forest Laboratories, Inc. (FRX) to Present Cariprazine Results From a Phase 3 Trial and Two Pharmacology Studies at the American College Neuropsychopharmacology (ACNP) Annual Meeting  
12/4/2012 10:54:19 AM

NEW YORK--(BUSINESS WIRE)--Forest Laboratories, Inc. (NYSE: FRX) today announced it will be presenting data on cariprazine at the American College of Neuropsychopharmacology Annual Meeting scheduled December 2-6, 2012 in Hollywood, FL. Forest Laboratories, Inc recently submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for cariprazine for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with Bipolar I disorder.